KimberlyLBlackwellMD

Oncology • Durham, NC

Associate Professor of Medicine, Duke University

Join to view full profile

Dr. Blackwell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Blackwell's full profile

Already have an account?

Office
Duke Medical Ctr
# 3893
Durham, NC 27710
Phone+1 919-668-1748

Fax+1 919-681-0874

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
Duke University HospitalResidency, Internal Medicine, 1994 - 1997
Mayo Clinic College of MedicineClass of 1994

Certifications & Licensure

NC State Medical License 1995 - 2025

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Most Compassionate Doctor American Registry
Join now to see all

Clinical Trials

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer Start of enrollment: 2006 Apr 01
Terminated
Phase 1
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain Start of enrollment: 2007 May 01
Terminated
Phase 2
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Phase II Dasatinib Study in Advanced Breast Cancer Start of enrollment: 2007 Oct 01
Completed
Phase 2
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis Start of enrollment: 2007 Nov 01
Completed
Phase 1, Phase 2
Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease Start of enrollment: 2007 Jun 01
Completed
Phase 1
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer Start of enrollment: 2011 Aug 01
Terminated
Phase 2
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Start of enrollment: 2012 Feb 01
Active, not recruiting
Phase 2
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Start of enrollment: 2012 Jul 12
Completed
Phase 1, Phase 2
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Start of enrollment: 2012 Sep 21
Completed
Phase 1
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

1171 citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke
The New England Journal of Medicine. 2016-10-07
2375 citations
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau
The New England Journal of Medicine. 2012-11-07
587 citations
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
Carey K. Anders, David S. Hsu, Gloria Broadwater, Chaitanya R. Acharya, John A. Foekens
Journal of Clinical Oncology. 2008-07-10

Lectures

Individualized Breast, GYN, and Colon Cancer Management; New Data and Updates Relevant to Patient Care
Mayo School of Continuous Professional Development, Jacksonville, Florida - 2/15/2013

Press Mentions

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational UpdatesNovember 9th, 2022
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational UpdatesNovember 9th, 2022
Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 MutationsJanuary 13th, 2022
Join now to see all